Granissetrom Aurovitas (Granisetron)

Granissetrom Aurovitas is indicated for the prevention of nausea and vomiting in specific clinical settings.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic cancer treatments.
• Prevention of postoperative nausea and vomiting (PONV) following surgical procedures that require anesthesia.
• Adjunct therapy for patients who have experienced inadequate control of emesis with other anti‑emetic agents.
• Use in combination with other anti‑emetic classes (e.g., corticosteroids or NK‑1 antagonists) as part of a multimodal regimen.

The safety profile of granisetron includes both frequently observed and rare adverse reactions.

Common

• Headache: mild to moderate head pain.
• Constipation: reduced bowel movements.
• Diarrhea: loose stools.
• Fatigue: feeling unusually tired.
• Dizziness: light‑headed sensation.

Serious

• Severe allergic reaction: signs may include rash, swelling, or difficulty breathing.
• Cardiac arrhythmias: rare cases of QT interval prolongation or other rhythm disturbances.

When prescribing Granissetrom Aurovitas, clinicians should consider several precautionary measures to ensure safe use.

• Assess baseline cardiac status, especially in patients with known QT prolongation risk.
• Use caution in individuals with hepatic impairment, as metabolism may be altered.
• Monitor for signs of hypersensitivity during initial dosing.
• Adjust therapy if concomitant medications that also prolong QT interval are required.
• Evaluate renal function in patients with severe renal disease, although granisetron is primarily hepatic cleared.
• Consider alternative anti‑emetics in pregnant or breastfeeding women due to limited safety data.

Granisetron may interact with other drugs, influencing its efficacy or safety profile.

Avoid

• Other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics) that could increase arrhythmia risk.
• Strong CYP3A4 inhibitors if the formulation relies on this pathway, as they may raise granisetron levels.

Use with caution

• Moderate CYP3A4 inducers (e.g., rifampin) that could reduce drug exposure.
• Concurrent use of other anti‑emetics, particularly other 5‑HT3 antagonists, due to additive effects.
• Drugs affecting electrolyte balance (e.g., diuretics) that may predispose to cardiac events.